Skip to content

Last week in biopharma partnering: May 22 – 28, 2022

By admin May 31, 2022

Each week (well almost, some weeks are quite uneventful), we compile and curate hot-off-the-press news and updates on the happenings in the world of pharma and life sciences partnering.

Be sure to follow us and keep up-to-date on all things partnering to inform your decisions and strategies.

KaliVir Immunotherapeutics announced a collaboration and global exclusive licensing agreement with Roche, to leverage KaliVir’s proprietary technology platform based on genetically modified vaccinia virus to discover and develop novel oncolytic virus candidates — see full article.

ImaginAb, Inc. announced the signing of an exclusive license with [Yantai] DongCheng Pharmaceutical Group to commercialize ImaginAb’s CD8 ImmunoPET agent (zirconium Zr 89 crefmirlimab berdoxam) in the Greater China market — see press release.

ArchiMed, a Trans-Atlantic PE, is the lead investor in an alliance recapitalizing Corealis Pharma – to further expand the high-quality drug development services Corealis offers as a Contract Development and Manufacturing Organization (CDMO) to small and medium-sized biotech and pharma companies – see press release.

Poolbeg Pharma has been granted patents by the US Patent and Trademark Office (USPTO) for POLB 001, a small molecule immunomodulator for the treatment of severe influenza and POLB 002, a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections — see full article.

MEDZnMORE’s, a online platform with existing partnerships with Getz Pharma, GSK, Shield, Mothercare, and other market leaders, signed an agreement with AGP, making this another major partnership with a leading pharmaceutical brand to provide consumer access to quality medicine — see full article.